EW - Edwards Lifesciences Corporation (EW) Q2 2024 Earnings Call Transcript
2024-07-24 21:45:28 ET
Edwards Lifesciences Corporation (EW)
Q2 2024 Earnings Conference Call
July 24, 2024 05:00 PM ET
Company Participants
Mark Wilterding - SVP & IR
Bernard Zovighian - CEO
Scott Ullem - CFO
Larry Wood - Group President of TAVR and Surgical Structural Heart
Daveen Chopra - Global Leader of TMTT
Conference Call Participants
Larry Biegelsen - Wells Fargo
Robbie Marcus - JPMorgan
David Roman - Goldman Sachs
Joshua Jennings - TD Cowen
Travis Steed - Bank of America
Matthew Taylor - Jefferies
Vijay Kumar - Evercore ISI
Patrick Wood - Morgan Stanley
Presentation
Operator
Greetings, and welcome to the Edwards Lifesciences Second Quarter 2024 Results. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It's now my pleasure to introduce your host, Mark Wilterding, Senior Vice President, Investor Relations. Thank you. You may begin.
Mark Wilterding
Thank you very much, Kevin. Good afternoon, and thank you all for joining us. With me on today's call is our CEO, Bernard Zovighian; and our CFO, Scott Ullem. Also joining us for the Q&A portion of the call will be Larry Wood, our Global President of TAVR and Surgical Structural Heart; Daveen Chopra, our Global Leader of TMTT; Wayne Markowitz, our Global Leader of Surgical Structural Heart; and Katie Szyman, our Global Leader of Critical Care.
Just after the close of regular trading, Edwards Lifesciences released second quarter 2024 financial results. During today's call, management will discuss those results included in the press release and accompanying financial schedules and then use the remaining time for Q&A.
Please note that management will be making forward-looking statements that are based on estimates, assumptions and projections. These statements include, but are not limited to, financial guidance and expectations for growth opportunities, strategy, leverage and integration of acquisitions, regulatory approvals, clinical trials, litigation, reimbursement, competitive matters and foreign currency fluctuations. These statements speak only as of the date on which they are made, and Edwards does not undertake any obligation to update them after today....
Edwards Lifesciences Corporation (EW) Q2 2024 Earnings Call Transcript